8-K: Inspire Medical Systems Reports Strong Q4 and Full Year 2024 Results, Updates 2025 Outlook

Inspire Medical Systems announces a 25% year-over-year revenue increase and a 135% earnings per share growth for the fourth quarter of 2024, along with reaffirming its full year 2025 revenue guidance.

Summary

• Inspire Medical Systems reported a revenue of $239.7 million for Q4 2024, a 25% increase compared to the same period last year.
• Full year 2024 revenue reached $802.8 million, representing a 28% increase over 2023.
• The company's gross margin for Q4 2024 was 85.0%.
• Net income for Q4 2024 was $35.2 million, with diluted net income per share at $1.15.
• For the full year 2024, net income was $53.5 million, and diluted net income per share was $1.75.
• Inspire activated 72 new U.S. centers in Q4 2024, bringing the total to 1,435.
• The company created 12 new U.S. sales territories in Q4 2024, totaling 335.
• Operating cash flow for Q4 2024 was $69.2 million, resulting in $130.2 million for the full year.
• Inspire reaffirms its full year 2025 revenue guidance of $940 million to $955 million, projecting a 17% to 19% year-over-year growth.
• The company introduces full year 2025 diluted net income per share guidance of $2.10 to $2.20.

Sentiment

Score: 9

Explanation: The document presents a highly positive outlook with strong financial results, growth projections, and strategic advancements. The management's comments are optimistic, and the overall tone suggests confidence in the company's future performance.

Positives

• Significant revenue growth in both Q4 2024 and full year 2024.
• Substantial increase in net income and diluted net income per share.
• Expansion of U.S. medical centers and sales territories.
• Strong operating cash flow generation.
• Positive full year 2025 revenue and earnings per share guidance.
• Successful launch of Inspire V.
• Initiation of a $75 million accelerated share repurchase program.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include commercial success and market acceptance of Inspire therapy, ability to achieve and maintain adequate levels of coverage or reimbursement, competitive landscape, dependence on third-party suppliers, and risks associated with international operations.
• The impact of glucagon-like peptide 1 class of drugs on demand for Inspire therapy is a risk factor.

Future Outlook

Inspire Medical Systems anticipates full year 2025 revenue to be in the range of $940 million to $955 million, representing a 17% to 19% growth over 2024. The company also projects full year 2025 diluted earnings per share to be between $2.10 and $2.20.

Management Comments

• Tim Herbert, Chairman and CEO, stated that they are thrilled with their strong performance in the fourth quarter, growing revenue 25% year-over-year and increasing diluted net income per share 135% year-over-year.
• Mr. Herbert mentioned steady progress toward the full launch of Inspire V, optimization of the leadership team, improvement in profitability, initiation of a $75 million accelerated share repurchase program, and reaching a milestone of over 90,000 patients treated with Inspire therapy.
• Mr. Herbert looks forward to continuing their strong performance in 2025 aided by the launch of Inspire V.

Industry Context

Inspire Medical Systems operates in the medical technology industry, specifically focusing on solutions for obstructive sleep apnea. The company's results reflect a growing demand for minimally invasive treatments in this space. The company competes with traditional treatments like CPAP and surgical options, as well as other emerging therapies.

Comparison to Industry Standards

• Inspire's gross margin of approximately 85% is very high compared to other medical device companies, suggesting a strong competitive advantage or premium pricing.
• Companies like ResMed, which also operate in the sleep apnea market, have lower gross margins, typically in the 50-60% range.
• The growth rate of 28% in revenue significantly outpaces the average growth rate of the broader medical device industry, indicating strong market penetration and adoption of Inspire therapy.
• The company's focus on neurostimulation technology differentiates it from companies primarily focused on CPAP devices.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance and growth prospects.
• Employees: Positive impact due to company growth and investment in organizational culture.
• Patients: Positive impact due to innovative therapy and improved patient experience.
• Medical Centers: Positive impact due to increased adoption of Inspire therapy.

Next Steps

• Full launch of Inspire V.
• Continued expansion of U.S. medical centers and sales territories.
• Ongoing investment in research and development.
• Further penetration of existing markets and entry into new geographical locations.
• Continued development of Inspire VI and VII for autoactivation and future auto-titration.

Key Dates